Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Frederick Welt Added: 7 months ago
Expand your understanding of acute coronary syndromes beyond traditional plaque rupture with Dr Frederick Welt.In this presentation, part of the Complex Cases track in Women As One's CLIMB® 2025 Skills Training Program, Dr Frederick Welt uses a compelling case study of a young woman with diabetes presenting with non-STEMI to demonstrate how advanced imaging reveals the full spectrum of coronary… View more
Added: 10 months ago Source:  Radcliffe Cardiology
AUTHOR: Sean DelaneyA greater number of traditional cardiovascular risk factors is strongly associated with increased coronary plaque vulnerability in patients with acute coronary syndrome (ACS), particularly in culprit lesions, according to a new analysis published in JACC.¹ The study provides a direct morphological link between the cumulative burden of risk factors and the high-risk plaque… View more
Author(s): Tiziana Claudia Aranzulla Added: 9 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Added: 6 months ago Source:  Radcliffe Cardiology
An artificial intelligence (AI) algorithm can identify high-risk coronary plaques on optical coherence tomography (OCT) images and predict adverse outcomes, according to findings from the PECTUS-AI study.¹ The research suggests that AI-assisted analysis of the entire imaged vessel provides superior prognostic value compared to manual analysis of a target lesion alone.Coronary thin-cap… View more
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more